Nicholas Tsakmaklis

发表

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.

Wei Zhang, P. Cohen, Shuai Liu, 2016, Blood.

BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism.

N. Gray, Jinhua Wang, S. Treon, 2018, Blood.

The HCK/BTK inhibitor KIN-8194 is active in MYD88 driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.

N. Munshi, N. Gray, Jinhua Wang, 2021, Blood.

Clonal architecture of CXCR4 WHIM‐like mutations in Waldenström Macroglobulinaemia

R. Advani, J. Zehnder, S. Treon, 2016, British journal of haematology.

Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy

S. Treon, Z. Hunter, A. Branagan, 2021, Blood advances.

Venetoclax in Previously Treated Waldenström Macroglobulinemia

R. Advani, M. Davids, S. Treon, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia

S. Treon, Z. Hunter, A. Branagan, 2021, HemaSphere.

Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy

S. Treon, Z. Hunter, A. Branagan, 2021, Haematologica.

Cell‐free DNA analysis for detection of MYD88L265P and CXCR4S338X mutations in Waldenström macroglobulinemia

T. P. White, S. Treon, Z. Hunter, 2021, American journal of hematology.

Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials

S. Treon, Z. Hunter, J. Castillo, 2020, HemaSphere.

Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.

S. Treon, A. Roccaro, A. Sacco, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia

S. Treon, Z. Hunter, J. Castillo, 2020, Leukemia & lymphoma.

Deepening of response after completing rituximab‐containing therapy in patients with Waldenstrom macroglobulinemia

S. Treon, Z. Hunter, J. Castillo, 2019, American journal of hematology.

CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia.

S. Treon, Z. Hunter, J. Castillo, 2019, Blood advances.

CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib

S. Treon, Z. Hunter, J. Castillo, 2019, British journal of haematology.

Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.

S. Treon, N. Raje, Z. Hunter, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MYD88 wild‐type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival

S. Treon, Z. Hunter, J. Castillo, 2018, British journal of haematology.

Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia

N. Gray, S. Treon, Z. Hunter, 2017, British journal of haematology.

Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.

R. Advani, S. Treon, Z. Hunter, 2017, Blood.

Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.

S. Treon, Z. Hunter, J. Castillo, 2016, Blood.

Mutated MYD88 Zygosity and CXCR4 Mutation Status Are Important Determinants of Ibrutinib Response and Progression Free Survival in Waldenstrom's Macroglobulinemia

R. Advani, S. Treon, Z. Hunter, 2016 .

Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up.

S. Treon, Z. Hunter, J. Castillo, 2020, Blood advances.